查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018434

混合成像市場：按技術類型、應用和最終用戶分類 - 2026-2032年全球市場預測

Hybrid Imaging Market by Technology Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，混合成像市場價值將達到 86 億美元，到 2026 年將成長至 91.9 億美元，到 2032 年將達到 137.2 億美元，複合年成長率為 6.90%。

主要市場統計數據
基準年 2025 86億美元
預計年份：2026年 91.9億美元
預測年份 2032 137.2億美元
複合年成長率 (%) 6.90%

對混合成像環境的權威介紹，重點關注臨床因素、技術融合以及醫療保健相關人員的策略重點。

混合影像技術融合了多種技術，契合了不斷變化的臨床需求和不斷發展的醫療保健系統的要求。近年來，臨床醫生和技術開發人員日益重視解剖成像和分子成像模式的整合，以提高診斷特異性和治療監測效果，同時致力於以患者為中心的工作流程和精準醫療。本文概述了決策者在評估混合成像技術現狀時應優先考慮的核心促進因素、相關人員的期望以及策略挑戰。

技術融合、監管改革和供應鏈重組如何共同重新定義混合成像技術對醫療服務提供者和製造商的價值提案。

在技​​術融合、監管環境演變和醫療服務模式變革的推動下，混合成像領域正經歷著一場變革。近年來，結合功能性影像和結構影像以提供更豐富診斷資訊的混合成像技術日益成熟，而影像處理和人工智慧軟體的進步也開始提升診斷的可靠性並簡化工作流程。伴隨這些技術進步，監管環境和支付方政策也在根據混合成像研究提供的證據進行調整，促使製造商和臨床研究人員設計能夠展現有意義的臨床終點的試驗。

評估 2025 年關稅調整對整個混合成像價值鏈的採購、服務連續性和總擁有成本的累積影響。

影響跨境貿易和零件關稅的政策變化，為依賴全球供應鏈的製造商、經銷商和醫療保健系統帶來了新的考慮。 2025年關稅調整的累積影響正在改變核心子系統、外圍組件和放射性藥物物流的成本結構，促使相關人員重新評估籌資策略和與供應商的合約條款。為此，許多機構正在探索近岸外包、供應商多元化以及簽訂長期採購協議，以降低未來貿易政策波動的風險。

詳細的細分洞察揭示了技術類型、銷售管道、臨床應用和最終用戶概況如何共同決定混合成像的採用和價值實現。

對市場區隔的精準理解有助於明確臨床需求、採購管道和技術偏好之間的交集，從而指導商業化和部署策略。在評估不同類型的技術時，臨床醫師和管理人員會區分PET-CT、PET-MRI和SPECT-CT產品，每種產品在敏感度、軟組織對比和面積都各具優勢。這些差異會影響資金配置、臨床方案和示蹤劑的使用。銷售管道也至關重要。選擇直銷或經銷商關係會影響合約的柔軟性、售後支援和地理覆蓋範圍，並進而影響服務和培訓專案。

美洲、歐洲、中東、非洲和亞太地區的區域趨勢和微妙的採用模式將決定差異化的市場進入和成長策略。

區域趨勢影響技術採納曲線、報銷環境和投資重點，為在美洲、歐洲、中東、非洲和亞太地區營運的相關人員創造了不同的機會和挑戰。在美洲，支付模式和大規模綜合醫療保健系統正在推動對能夠顯著改善臨床流程的高通量解決方案的需求。同時，區域領先的醫療中心和研究網路正在加速臨床實踐中的早期應用和方案標準化。資金的取得和一體化的採購系統簡化了採購流程，同時也更重視可驗證的成果。

一項關鍵的企業級策略，結合臨床夥伴關係、卓越服務和生態系統整合，以確保在混合成像領域獲得永續的競爭優勢。

混合成像領域的競爭格局不僅取決於系統效能，還取決於臨床夥伴關係、售後支援和生態系統整合。領先機構正投資於合作研究計畫、多中心檢驗試驗和培訓舉措，以減少臨床應用障礙，並與關鍵意見領袖 (KOL) 建立長期合作關係。與放射性藥物開發公司和軟體供應商建立策略合作夥伴關係日益普遍，從而能夠提供涵蓋成像硬體和示蹤劑研發管線的捆綁式解決方案。

為供應商和提供者提供最佳化產品設計、供應彈性、商業化模式和臨床合作的實用建議，以成功實現混合成像。

行業領導企業應採取多管齊下的方法，使產品開發、商業化和臨床合作與醫療保健系統不斷變化的優先事項保持一致。首先，他們應優先考慮模組化系統結構和可互通的軟體平台，以促進升級並與電子健康記錄(EHR) 和腫瘤資訊系統整合。這將降低客戶更新成本，並透過利用現有的數位化工作流程來加速臨床部署。其次，他們應投資於透過合作試驗和真實世界研究來產生臨床證據，以證明其對診斷信心、患者管理和診療路徑的影響，而不是僅僅關注技術性能指標。

採用穩健的混合方法研究途徑，結合對關鍵相關人員的訪談、二手臨床文獻和嚴格的檢驗，確保對混合成像有實證的見解。

本研究整合了訪談資料、文獻資料以及對臨床和政策趨勢的系統性回顧，以確保提供平衡且檢驗的見解。訪談資料包括對臨床醫生、放射科管理人員、採購經理和技術專家的深入訪談，從而獲得關於臨床工作流程、採購標準和服務期望的第一手觀點。文獻資料包括同行評審的臨床研究、監管指南和公開的政策分析，用於分析技術採納和報銷方面的趨勢。

簡明扼要的結論重點闡述了將混合成像創新轉化為可衡量的臨床和系統級價值所需的策略機會和營運挑戰。

本文提出的綜合分析表明，混合成像代表著診斷醫學的一個策略轉折點，它將技術創新與臨床工作流程和醫療保健系統目標聯繫起來。多種影像方式的融合、分析工具的成熟以及不斷演進的放射性藥物組合，為提高診斷特異性、實現個人化治療方案和增強臨床決策能力創造了機會。同時，政策和供應鏈的變化凸顯了製定具有韌性的商業策略和靈活的部署模式的必要性，以適應不斷變化的成本結構和法規環境。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 混合影像市場：依技術類型分類

  • PET-CT
  • PET-MRI
  • SPECT-CT

第9章：混合影像市場：依應用分類

  • 循環系統
    • 心肌灌注
    • 可行性
  • 感染疾病
    • 感染部位影像
    • 發炎成像
  • 神經病學
    • 癲癇
    • 神經退化性疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤

第10章 混合成像市場：依最終用戶分類

  • 診斷中心
  • 醫院
  • 研究機構

第11章：混合影像市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 混合影像市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：混合成像市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國混合影像市場

第15章：中國混合影像市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • Cubresa Inc.
  • GE Healthcare Technologies Inc.
  • Mediso Medical Imaging Systems Ltd.
  • MILabs BV
  • Miltenyi Biotec BV & Co. KG
  • MR Solutions Ltd.
  • Philips Healthcare（Koninklijke Philips NV）
  • Raycan Technology Co., Ltd.
  • Siemens Healthineers AG
  • TriFoil Imaging, Inc.
Product Code: MRR-0360AB17DFF6

The Hybrid Imaging Market was valued at USD 8.60 billion in 2025 and is projected to grow to USD 9.19 billion in 2026, with a CAGR of 6.90%, reaching USD 13.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.60 billion
Estimated Year [2026] USD 9.19 billion
Forecast Year [2032] USD 13.72 billion
CAGR (%) 6.90%

An authoritative introduction to the hybrid imaging environment emphasizing clinical drivers, technology convergence, and strategic priorities for healthcare stakeholders

Hybrid imaging is at the intersection of converging technologies, shifting clinical priorities, and evolving health system imperatives. Over recent years clinicians and technology developers have increasingly integrated anatomical and molecular modalities to improve diagnostic specificity and therapeutic monitoring, driving a focus on patient-centric workflows and precision medicine. This introduction outlines the core drivers, stakeholder expectations, and the strategic questions that decision-makers should prioritize when evaluating the hybrid imaging landscape.

Adoption patterns are influenced by the need for higher diagnostic confidence in complex indications, greater operational efficiency across imaging suites, and the pursuit of quantifiable outcomes that support reimbursement. Simultaneously, technological innovations in detector design, image fusion, and radiopharmaceutical development are enabling novel clinical use cases. As a result, providers are assessing capital acquisition strategies in the context of long-term clinical programs rather than single-use investments.

Clinicians and administrators must balance capital intensity with potential gains in diagnostic throughput, reduced downstream procedures, and improved patient management. Consequently, strategy conversations should integrate clinical pathways, vendor partnerships, and training programs to ensure that hybrid imaging assets deliver sustained value across the care continuum.

How technological convergence, regulatory recalibration, and supply chain realignment are jointly redefining value propositions in hybrid imaging for care providers and manufacturers

The hybrid imaging landscape is experiencing transformative shifts driven by technological convergence, regulatory evolution, and changing care delivery models. Recent years have seen the maturation of hybrid modalities that combine functional and structural imaging to deliver richer diagnostic context, while software advances in image processing and AI have begun to enhance diagnostic confidence and workflow efficiency. Parallel to these technical developments, regulatory frameworks and payer policies are adapting to evidence generated from hybrid studies, prompting manufacturers and clinical investigators to design trials that demonstrate meaningful clinical endpoints.

Supply chain realignment and component sourcing strategies are reshaping procurement and manufacturing decisions, encouraging modular designs and closer collaboration between system integrators and radiopharmaceutical suppliers. Clinical practice is also evolving; multidisciplinary teams are increasingly relying on hybrid imaging to inform personalized treatment plans, particularly in oncology and neurology, where molecular signatures guide therapeutic choices. Taken together, these shifts are not incremental but systemic: they redefine value propositions from purely hardware-centric to integrated clinical solutions encompassing devices, tracers, analytics, and service models.

Assessing the cumulative implications of 2025 tariff adjustments on sourcing, service continuity, and total cost of ownership across hybrid imaging value chains

Policy changes affecting cross-border trade and component tariffs have introduced new considerations for manufacturers, distributors, and health systems that rely on global supply chains. The cumulative impact of tariff adjustments in 2025 has altered cost structures for core subsystems, peripheral components, and radiopharmaceutical logistics, prompting stakeholders to reassess sourcing strategies and contractual terms with suppliers. In response, many organizations have explored nearshoring, diversified vendor bases, and longer-term procurement agreements to mitigate exposure to future trade policy volatility.

Clinicians and hospital finance teams are experiencing indirect effects through slower delivery timelines for capital equipment and increased lead times for replacement parts, which can influence equipment uptime and scheduling. Distributors and service providers have had to revise warranty terms and service-level agreements to accommodate changed cost bases, while manufacturers are reconsidering global production footprints to protect margins without compromising regulatory compliance and quality control.

Importantly, the tariff-driven environment has accelerated discussions about total cost of ownership, emphasizing maintenance, training, and clinical utilization as critical levers to preserve value. For stakeholders focused on long-term programs, the immediate policy-driven cost pressures have underscored the importance of contractual flexibility, collaborative supply relationships, and scenario planning to maintain continuity of care delivery and technology deployment.

Deep segmentation insights revealing how technology type, sales channels, clinical applications, and end-user profiles jointly determine hybrid imaging adoption and value realization

A nuanced understanding of segmentation clarifies where clinical demand, procurement pathways, and technology preferences intersect, shaping commercialization and deployment strategies. When evaluating technology types, clinicians and administrators differentiate offerings across PET-CT, PET-MRI, and SPECT-CT, each delivering distinct advantages in sensitivity, soft-tissue contrast, and operational footprint; these differences influence capital allocation, clinical protocols, and tracer utilization. Sales channels also matter: choices between direct sales engagements and distributor relationships affect contract flexibility, aftermarket support, and regional reach, with implications for service coverage and training programs.

Application-focused segmentation reveals how diagnostic priorities drive modality selection and protocol development. Cardiology applications, including myocardial perfusion and viability studies, demand consistent quantitative performance and streamlined workflows to support high-throughput cardiac programs. Infectious disease imaging, broken down into infection site imaging and inflammation imaging, requires flexible tracer options and rapid imaging timelines to inform acute care decisions. Neurology applications such as epilepsy and neurodegenerative evaluations benefit from high-resolution molecular mapping and standardized interpretation frameworks. Oncology practices, spanning hematologic malignancies and solid tumors, rely heavily on precise staging and response assessment to optimize therapeutic sequencing.

End-user profiles determine procurement cycles and utilization models, with diagnostic centers often prioritizing throughput and referral networks, hospitals emphasizing integrated care pathways and multidisciplinary access, and research institutes focusing on protocol flexibility and tracer development. Understanding how these dimensions interact enables tailored commercial strategies that align product features, service models, and clinical support with the distinct needs of each segment.

Regional dynamics and nuanced adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate differentiated market entry and growth strategies

Regional dynamics shape adoption curves, reimbursement landscapes, and investment priorities, creating differentiated opportunities and constraints for stakeholders operating across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, payer models and large integrated health systems drive demand for high-throughput solutions that demonstrate clear care pathway improvements, while regional centers of excellence and research networks accelerate early clinical adoption and protocol standardization. Access to capital and consolidated purchasing structures can streamline procurement but also increase emphasis on demonstrable outcomes.

In Europe, Middle East & Africa, heterogeneous regulatory environments and reimbursement structures create a mosaic of adoption patterns; centralized national systems in some countries contrast with more fragmented markets in others, affecting how vendors approach market entry and service delivery. Regional health priorities, such as oncology networks and neurology centers, guide investment in hybrid capabilities and radiopharmaceutical access. By contrast, the Asia-Pacific region is characterized by rapid capacity expansion, increasing investments in advanced imaging infrastructure, and growing domestic manufacturing capabilities that influence pricing and supply resilience. Demographic trends and rising chronic disease burdens in several markets expedite demand for precision diagnostics, while varying regulatory timelines shape the pace of clinical integration.

Recognizing these regional distinctions supports tailored go-to-market strategies, localized evidence generation, and service models that reflect reimbursement realities and the maturity of clinical networks.

Critical company-level strategies that combine clinical partnerships, service excellence, and ecosystem integration to secure durable competitive advantage in hybrid imaging

Competitive landscapes in hybrid imaging are defined not only by system performance but also by clinical partnerships, aftermarket support, and ecosystem integration. Leading organizations are investing in collaborative research programs, multi-center validation studies, and training initiatives that lower barriers to clinical adoption and create durable relationships with key opinion leaders. Strategic alliances with radiopharmaceutical developers and software providers are increasingly common, enabling bundled solutions that address both imaging hardware and tracer pipelines.

Service excellence is another differentiator; companies that provide predictable maintenance, rapid parts availability, and robust remote diagnostics enhance equipment uptime and customer satisfaction. Commercial models are also evolving from standalone capital sales toward outcome-oriented service contracts and managed service agreements that align vendor incentives with clinical utilization and patient outcomes. Additionally, intellectual property in detector technology, image reconstruction algorithms, and tracer chemistry contributes to competitive positioning, while flexible deployment models and financing options help address budgetary constraints in diverse healthcare settings.

Market participants that balance technological innovation with pragmatic service delivery and clinician engagement are better positioned to capture long-term contracts, participate in clinical networks, and influence care protocols.

Actionable recommendations for vendors and providers to optimize product design, supply resilience, commercialization models, and clinical engagement for hybrid imaging success

Industry leaders should adopt a multi-pronged approach that aligns product development, commercialization, and clinical engagement with evolving health system priorities. First, prioritize modular system architectures and interoperable software platforms to facilitate upgrades and integration with electronic health records and oncology information systems. This reduces refresh costs for customers and accelerates clinical adoption by leveraging existing digital workflows. Second, invest in clinical evidence generation through collaborative trials and real-world studies that demonstrate impact on diagnostic confidence, patient management, and care pathways rather than focusing solely on technical performance metrics.

Third, strengthen supply resilience by diversifying supplier networks, establishing regional service hubs, and exploring nearshore manufacturing options to mitigate tariff and logistics risks. Fourth, develop flexible commercial models including managed service agreements, outcome-based contracts, and training bundles that support scalable deployments across hospitals, diagnostic centers, and research institutes. Fifth, build strategic partnerships with radiopharmaceutical developers and AI analytics providers to offer integrated solutions that address tracer availability, quantitative imaging, and decision support.

Finally, commit to clinician-focused education and change management programs that support protocol standardization, cross-disciplinary collaboration, and the effective translation of hybrid imaging insights into treatment decisions. These combined actions will help organizations convert technological capabilities into sustainable clinical and commercial value.

A robust mixed-methods research approach combining primary stakeholder interviews, secondary clinical literature, and rigorous triangulation to ensure evidence-based hybrid imaging insights

This research synthesizes primary interviews, secondary literature, and a structured review of clinical and policy developments to ensure balanced and validated findings. Primary research includes in-depth interviews with clinicians, radiology administrators, procurement leaders, and technical specialists who provide firsthand perspectives on clinical workflows, purchasing criteria, and service expectations. Secondary inputs encompass peer-reviewed clinical studies, regulatory guidance, and publicly available policy analyses that contextualize technology adoption and reimbursement dynamics.

Quantitative and qualitative data were triangulated through a rigorous validation process that included cross-referencing interview insights with documented clinical protocols and supplier service offerings. Comparative analysis of technology types and application areas was performed using documented clinical use cases and protocol standardization efforts. Limitations of the methodology include reliance on available published evidence and stakeholder willingness to discuss commercial specifics; to mitigate these constraints, the analysis emphasizes aggregated and anonymized insights and applies conservative interpretations where evidence was limited.

Ethical considerations and data governance protocols were observed throughout the research process, and findings were reviewed by multidisciplinary experts to ensure clinical plausibility and operational relevance.

A concise conclusion underscoring the strategic opportunity and operational imperatives required to translate hybrid imaging innovations into measurable clinical and system-level value

The synthesis presented here emphasizes that hybrid imaging represents a strategic inflection point for diagnostic medicine, connecting technological innovation with clinical workflows and health system objectives. The convergence of modalities, maturation of analytic tools, and evolving radiopharmaceutical portfolios create opportunities to improve diagnostic specificity, personalize treatment pathways, and enhance clinical decision-making. At the same time, policy and supply chain shifts underscore the need for resilient commercial strategies and flexible deployment models that can adapt to changing cost structures and regulatory environments.

For stakeholders across the value chain, the imperative is to translate technical capabilities into measurable clinical value through collaborative evidence generation, targeted clinical programs, and service models that support sustained utilization. By aligning product development with clinician needs and building durable operational support, organizations can ensure that hybrid imaging assets deliver meaningful improvements in patient management and system efficiencies. The path forward requires coordinated investments in evidence, infrastructure, and partnerships to fully realize the promise of hybrid imaging in modern healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hybrid Imaging Market, by Technology Type

  • 8.1. Pet-CT
  • 8.2. Pet-MRI
  • 8.3. Spect-CT

9. Hybrid Imaging Market, by Application

  • 9.1. Cardiology
    • 9.1.1. Myocardial Perfusion
    • 9.1.2. Viability
  • 9.2. Infectious Diseases
    • 9.2.1. Infection Site Imaging
    • 9.2.2. Inflammation Imaging
  • 9.3. Neurology
    • 9.3.1. Epilepsy
    • 9.3.2. Neurodegenerative
  • 9.4. Oncology
    • 9.4.1. Hematologic Malignancies
    • 9.4.2. Solid Tumors

10. Hybrid Imaging Market, by End User

  • 10.1. Diagnostic Centers
  • 10.2. Hospitals
  • 10.3. Research Institutes

11. Hybrid Imaging Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Hybrid Imaging Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Hybrid Imaging Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Hybrid Imaging Market

15. China Hybrid Imaging Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Bruker Corporation
  • 16.6. Canon Medical Systems Corporation
  • 16.7. Cubresa Inc.
  • 16.8. GE Healthcare Technologies Inc.
  • 16.9. Mediso Medical Imaging Systems Ltd.
  • 16.10. MILabs B.V.
  • 16.11. Miltenyi Biotec B.V. & Co. KG
  • 16.12. MR Solutions Ltd.
  • 16.13. Philips Healthcare (Koninklijke Philips N.V.)
  • 16.14. Raycan Technology Co., Ltd.
  • 16.15. Siemens Healthineers AG
  • 16.16. TriFoil Imaging, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HYBRID IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HYBRID IMAGING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HYBRID IMAGING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HYBRID IMAGING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HYBRID IMAGING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HYBRID IMAGING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES HYBRID IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA HYBRID IMAGING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HYBRID IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HYBRID IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HYBRID IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 142. GCC HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 166. G7 HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 174. NATO HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. NATO HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES HYBRID IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA HYBRID IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)